Meet Cyto-Mine® Chroma: the next-generation platform for functional characterization and selection of live single cells
Duration: 30 minutes; Richard Hammond Solutions Spotlight Talk, SLAS 2025
Are you ready to explore how Cyto-Mine® Chroma is paving the way for more efficient and high-throughput multiplexing screening? Join us for an exclusive webinar where Richard Hammond, CTO of Sphere Bio, illustrates how the newly launched Cyto-Mine® Chroma enables advanced cellular characterization via fluorescent multiplexing.
In this webinar, Richard showcases how Cyto-Mine Chroma is transforming antibody discovery and cell line development with its innovative multiplexing capabilities. This enables researchers to achieve unmatched precision and accelerate their projects.
Introduction
Therapeutic development and manufacture rely on characterizing cells and selecting sub-populations quickly and cost-effectively. In this talk, we introduce Cyto-Mine Chroma, our next-generation microfluidic-based platform that significantly enhances characterization to identify the top-performing cells.
We show how fluorescent multiplexing can be applied to high-throughput picodroplet-based assays to extend the range of assay formats and allow simultaneous measurements on millions of individual live cells, significantly increasing the overall specificity of selection while retaining the cell for future use.
Key Takeaways:
Watch Now!
Watch this webinar and learn how the novel Cyto-Mine® Chroma platform drives innovation in cell line development, biologics discovery, and cell therapy applications.
Keywords: Sphere Bio, picodroplet technology, biologics discovery, scale-up automation, biopharma innovation, single-cell analysis, Sphere Bio webinar, biotechnology automation, biologics production.
